BridgeBio Pharma Return on Tangible Equity 2018-2026 | BBIO
Current and historical return on tangible equity values for BridgeBio Pharma (BBIO) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| BridgeBio Pharma Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2026-03-31 | $-0.72B | $-2.04B | 35.40% |
| 2025-12-31 | $-0.73B | $-1.88B | 38.52% |
| 2025-09-30 | $-0.80B | $-1.73B | 46.16% |
| 2025-06-30 | $-0.78B | $-1.55B | 50.07% |
| 2025-03-31 | $-0.67B | $-1.38B | 48.52% |
| 2024-12-31 | $-0.54B | $-1.22B | 43.71% |
| 2024-09-30 | $-0.44B | $-1.20B | 36.63% |
| 2024-06-30 | $-0.45B | $-1.19B | 38.06% |
| 2024-03-31 | $-0.54B | $-1.26B | 42.77% |
| 2023-12-31 | $-0.64B | $-1.30B | 49.37% |
| 2023-09-30 | $-0.61B | $-1.28B | 47.96% |
| 2023-06-30 | $-0.57B | $-1.26B | 45.40% |
| 2023-03-31 | $-0.43B | $-1.18B | 36.06% |
| 2022-12-31 | $-0.48B | $-1.14B | 42.35% |
| 2022-09-30 | $-0.49B | $-1.05B | 46.86% |
| 2022-06-30 | $-0.51B | $-0.95B | 53.42% |
| 2022-03-31 | $-0.60B | $-0.81B | 73.80% |
| 2021-12-31 | $-0.56B | $-0.64B | 88.40% |
| 2021-09-30 | $-0.54B | $-0.38B | 140.33% |
| 2021-06-30 | $-0.50B | $-0.13B | 377.86% |
| 2021-03-31 | $-0.52B | $0.07B | -803.09% |
| 2020-12-31 | $-0.45B | $0.27B | -163.72% |
| 2020-09-30 | $-0.40B | $0.37B | -109.76% |
| 2020-06-30 | $-0.35B | $0.44B | -78.15% |
| 2020-03-31 | $-0.29B | $0.36B | -80.55% |
| 2019-12-31 | $-0.26B | $0.25B | -104.42% |
| 2019-06-30 | $-0.16B | 0 | 0.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $14.460B | $0.502B |
| BridgeBio Pharma Inc. is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio Pharma Inc. is based in PALO ALTO, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |